Boston Scientific Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael F. Mahoney
- Full Time Employees
- 53,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 300 Boston Scientific Way Marlborough MA United States of America 01752-1234
- IPO Date
- May 19, 1992
- CIK
- 0000885725
- Website
- bostonscientific.com
- Similar Companies
- Business
- Boston Scientific Corporation (NYSE: BSX) develops, manufactures and markets innovative medical devices for a wide range of interventional medical specialties worldwide. The company operates through two primary reportable segments, MedSurg and Cardiovascular, encompassing eight core businesses: Cardiac Rhythm Management, Electrophysiology, Endoscopy, Interventional Cardiology Therapies, Neuromodulation, Peripheral Interventions, Urology and WATCHMAN; its product portfolio includes pacemakers, defibrillators (S-ICD, ICD), CRT-P devices, deep brain stimulation systems, radiofrequency ablation systems for pain management, renal denervation technologies, direct visualization systems, embolic protection and embolization devices, FFR and IVUS systems, guidewires, imaging systems, intragastric balloons, lasers for BPH and lithotripsy, plaque modification tools, retrieval devices, RF ablation systems, hemostasis needles, hepatopancreatobiliary stents, hydrogel spacers, infection prevention products, pelvic floor reconstruction devices, penile prostheses and single-use imaging systems. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company maintains commercial operations in over 127 countries, including the U.S., Europe, Middle East and Africa, Asia-Pacific, Latin America and Canada, serving approximately 44 million patients annually through healthcare professionals in fields such as interventional cardiology, endoscopy, neuromodulation, peripheral interventions and urology. In recent developments, Boston Scientific has pursued an aggressive acquisition strategy, including agreements to acquire Bolt Medical for up to $664 million to enhance its intravascular lithotripsy offerings for coronary and peripheral artery disease (expected close in first half of 2025), SoniVie Ltd. for up to $600 million to advance therapeutic intravascular ultrasound for renal denervation in hypertension treatment (expected close in first half of 2025), Elutia's BioEnvelope division to reduce complications in cardiac rhythm management devices, Anrei Medical for $182 million to bolster endoscopy solutions, Intera Oncology for interventional oncology in liver metastases, and Cortex; the company also completed its $3.7 billion acquisition of Axonics in November 2024 and received $2.6 million in state funding for a 52,000-square-foot manufacturing expansion at its Maple Grove, Minnesota campus to support WATCHMAN product growth, alongside launching approximately 100 new products in 2024.
Belo Sun Announces Management Transition
Boston Scientific (BSX) Rises Higher Than Market: Key Facts
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
Why These Three Big Buybacks Are Sending Very Different Signals to Investors
Belo Sun Announces Corporate Update
Zscaler, AutoZone, And Regencell Are Among Top 10 Large-Cap Losers Last Week (May 25-May 29): Are The Others In Your Portfolio?
Boston Scientific Corporation (BSX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
BSX vs. ABT: Which Medical Stock Has More Upside Potential?
Why Boston Scientific Stock Was Sliding This Week
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts
This Boston Scientific Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday
Here Are Thursday’s Top Wall Street Analyst Research Calls: Agilent, Boston Scientific, Comfort Systems, Dick’s Sporting Goods, Dominion Energy, Electronic Arts, First Solar, Trade Desk, Valvoline, and More
Butterfield Announces Agreement to Acquire Control of CIBC Caribbean in $1.8 Billion Transaction
Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
Boston Scientific Is Betting $1.5 Billion on a Massive Market -- and Wall Street Is Paying Attention
BSX Fairly Valued by DCF at $51
Belo Sun Announces 2026 Shareholder Meeting Voting Results and Corporate Update
Boston Scientific Bets on WATCHMAN to Drive Structural Heart Growth
Why Is Boston Scientific (BSX) Down 13% Since Last Earnings Report?
Belo Sun Provides Update on Ongoing Proceedings Before TRF-1